Back to search

Article

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

2024-09-10

Abstract excerpt

<h4>Background: </h4> Lung cancer remains the leading cause of cancer-related mortality globally, predo-minantly affecting older individuals. Despite the increasing use of immune checkpoint inhibitors (ICIs) like nivolumab in non-small cell lung cancer (NSCLC), the efficacy and safety in elderly pa-tients, particularly those aged 65 and above, remain underexplored due to their underrepresenta-tion in clinical tria...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6da0e2c8-4110-55b9-a69a-639c59126c2c
DOI
10.20944/preprints202409.0812.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and OlderDOI 10.20944/preprints202409.0812.v1
Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity
Real-world study of first-line therapy with aumolertinib for elderly patients with non-small cell lung cancer harboring EGFR mutation.Semantic proximity
Real-world study of first-line therapy with aumolertinib for elderly patients with non‑small cell lung cancer harboring EGFR mutationSemantic proximity
Chronological Age Is Not an Independent Determinant of Survival or Treatment Access in Metastatic Non–Small Cell Lung Cancer: A Real-World Cohort StudySemantic proximity
Oncological therapy in stage IV lung cancer patients at the end-of-life – A retrospective single-center cohort analysis in the era of tyrosine kinase inhibition and immunotherapySemantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in advanced non-small cell lung cancer: A systematic review of randomized controlled trialsSemantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
Stage IV Non-small Cell Lung Adenocarcinoma in Complete Response for 5 Years Post-first-line Nivolumab Immunotherapy: Are We Talking about a Cure?Semantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity
The Predictive efficacy of tumor mutational burden for immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trialsSemantic proximity
Select a neighboring publication to make it the new centre.